PROCEPT BioRobotics (PRCT) AI Stock Analysis

• Market Cap: $1.75B
• Dividend Yield: N/A
• Average Volume (3M): 1.30M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: 50.07%
• EPS Growth: 21.22%
• Country: US
• Employees: 756
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.38
• Shares Outstanding: 55,878,590
• 10 Day Avg. Volume: 1,753,810
• 30 Day Avg. Volume: 1,298,530
• PEG Ratio: 2.10
• Price to Book (P/B): 10.43
• Price to Sales (P/S): 18.70
• P/FCF Ratio: -40.50
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 5.91
• Enterprise Value/Gross Profit: 9.16
• Enterprise Value/Ebitda: -22.89
• 1Y Price Target: $54.57
• Price Target Upside: 74.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -1.48
• Revenue Forecast (FY): $326.55M

• Rating: 41 Neutral
• Price Target: $30.00 ▼(-4.15% Downside)

The overall stock score is primarily influenced by the company's financial performance and technical analysis. Despite strong revenue growth, the company struggles with profitability and cash flow, which is reflected in a low valuation score. The technical indicators suggest a bearish trend, further impacting the overall score.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for PROCEPT's products, enhancing its market position and supporting long-term business expansion.

Gross Margin Expansion

Improved gross margins suggest better cost management and pricing power, which can lead to enhanced profitability over time.

International Revenue Growth

Strong international revenue growth highlights successful global expansion efforts, diversifying revenue streams and reducing reliance on domestic markets.

Negative Factors

Net Loss Persistence

Ongoing net losses indicate challenges in achieving profitability, which may hinder long-term financial health and investor confidence.

Negative Cash Flow

Negative cash flow suggests liquidity issues, potentially limiting the company's ability to invest in growth opportunities and manage debt.

Utilization Growth Challenges

Sluggish utilization growth may reflect market saturation or competitive pressures, impacting future sales and operational efficiency.

PROCEPT BioRobotics Business Overview & Revenue Model

Company Description

PROCEPT BioRobotics (PRCT) is a medical technology company focused on advancing robotic-assisted surgical solutions for urology. The company specializes in developing innovative products and services that enhance the precision and safety of surgical procedures, particularly for prostate surgery. PROCEPT’s flagship product, the AQUABEAM Robotic System, utilizes advanced robotics and real-time imaging technology to perform minimally invasive treatments with improved patient outcomes.

How the Company Makes Money

PROCEPT BioRobotics generates revenue primarily through the sale of its AQUABEAM Robotic System, which is complemented by disposable instruments and accessories used in surgical procedures. The company typically earns money from the initial sale of the robotic systems, which are sold to hospitals and surgical centers, as well as recurring revenue from the sale of consumable products required for each procedure. Additionally, PROCEPT may engage in partnerships with healthcare providers and institutions to enhance its market reach and implement its technologies in a broader range of healthcare settings, contributing to its overall earnings. These partnerships often facilitate training, adoption, and integration of its systems into clinical practice, thereby driving further sales and increasing the company's revenue base.

PROCEPT BioRobotics Financial Statement Overview

Summary

PROCEPT BioRobotics shows strong revenue growth and improving gross profit margins but struggles with profitability and cash flow generation. The balance sheet is stable with moderate leverage, yet the company faces challenges in achieving positive returns on equity.

Income Statement

PROCEPT BioRobotics shows a consistent revenue growth trajectory, with a notable 9.08% increase in TTM. However, the company struggles with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has improved over time, reaching 64.55% in TTM, indicating efficient cost management. Despite these improvements, the persistent negative net income and EBIT margins highlight ongoing challenges in achieving profitability.

Balance Sheet

The company's balance sheet reflects a stable debt-to-equity ratio of 0.21 in TTM, indicating moderate leverage. However, the return on equity remains negative, suggesting that the company is not generating sufficient returns on shareholders' equity. The equity ratio is not explicitly provided, but the overall asset base appears solid. The balance sheet stability is a positive, but the lack of profitability remains a concern.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows. The free cash flow growth rate is negative, indicating deteriorating cash generation capabilities. However, the free cash flow to net income ratio is above 1, suggesting that cash flow is relatively better than net income. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	299.91M	224.50M	136.19M	75.01M	34.47M	7.72M
Gross Profit	193.59M	137.10M	71.05M	37.09M	15.87M	-1.25M
EBITDA	-77.49M	-82.00M	-98.09M	-79.13M	-50.72M	-44.90M
Net Income	-84.58M	-91.41M	-105.90M	-87.15M	-59.85M	-53.02M
Balance Sheet
Total Assets	511.54M	534.02M	404.72M	309.33M	337.02M	125.97M
Cash, Cash Equivalents and Short-Term Investments	294.28M	333.73M	257.22M	221.86M	304.32M	100.13M
Total Debt	78.93M	80.25M	79.20M	77.32M	54.10M	54.76M
Total Liabilities	131.26M	131.80M	123.97M	112.26M	69.93M	308.87M
Stockholders Equity	380.28M	402.22M	280.75M	197.07M	267.09M	-182.89M
Cash Flow
Free Cash Flow	-79.73M	-103.62M	-133.21M	-83.03M	-57.93M	-48.58M
Operating Cash Flow	-71.05M	-99.21M	-108.00M	-80.38M	-57.33M	-48.34M
Investing Cash Flow	-8.68M	-4.41M	-25.21M	-2.65M	-592.00K	-233.00K
Financing Cash Flow	177.28M	180.13M	167.79M	3.61M	262.12M	106.77M

PROCEPT BioRobotics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 31.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRCT, the sentiment is Negative. The current price of 31.3 is below the 20-day moving average (MA) of 34.18, below the 50-day MA of 36.02, and below the 200-day MA of 51.82, indicating a bearish trend. The MACD of -0.99 indicates Positive momentum. The RSI at 37.83 is Neutral, neither overbought nor oversold. The STOCH value of 14.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRCT.

PROCEPT BioRobotics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INSP	71 Outperform	$2.41B	57.48	6.54%	―	16.81%	34.90%
AORT	62 Neutral	$2.19B	―	-2.45%	―	9.81%	-1066.50%
ATEC	58 Neutral	$2.93B	―	-540.40%	―	27.11%	17.66%
LIVN	52 Neutral	$2.77B	―	-17.63%	―	8.97%	-1024.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SSII	44 Neutral	$1.43B	―	-43.42%	―	159.43%	67.42%
PRCT	41 Neutral	$1.75B	-20.75	-27.22%	―	50.07%	21.22%

PROCEPT BioRobotics Corporate Events

Procept Biorobotics Earnings Call: Growth Amid Challenges

Procept Biorobotics Corp. recently held its earnings call, revealing a mixed sentiment among investors and stakeholders. The company reported impressive revenue growth and a notable increase in both U.S. and international sales, alongside positive gross margin expansion. However, concerns were raised due to persistent net losses, challenges in utilization growth, and potential procedural headwinds. Despite these challenges, the company remains optimistic about its strategic initiatives and long-term growth potential.

PROCEPT BioRobotics Reports Strong Q3 Growth and Optimistic 2026 Outlook

PROCEPT BioRobotics Corporation is a surgical robotics company specializing in innovative solutions for urology, notably through its AQUABEAM and HYDROS Robotic Systems, which provide Aquablation therapy for benign prostatic hyperplasia (BPH).

Procept Biorobotics’ WATER IV Study: A Game Changer in Prostate Cancer Treatment?

Study Overview: The WATER IV Prostate Cancer study, officially titled ‘WATER IV Prostate Cancer: Aquablation Versus Radical Prostatectomy for the Treatment of Localized Prostate Cancer,’ is a multicenter, prospective, randomized clinical trial. It aims to evaluate the safety and efficacy of Aquablation Therapy in men with localized prostate cancer who are candidates for prostatectomy. This study is significant as it explores a less invasive treatment option compared to traditional surgery.

Procept Biorobotics’ Aquablation Therapy Study: A Potential Game-Changer for Prostate Treatment

Procept Biorobotics Corp. is conducting a clinical study titled PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs to evaluate the performance and safety of the AQUABEAM Robotic System. This system is intended for the resection and removal of prostate tissue in patients with lower urinary tract symptoms and localized prostate cancer. The study aims to provide insights into the system’s effectiveness and safety over a 12-month period.

PROCEPT BioRobotics Updates Executive Severance Agreements

On September 15, 2025, PROCEPT BioRobotics Corporation’s Compensation Committee approved modifications to the Change of Control and Severance Agreement for executive officers below the CEO level. These changes include extending the severance period, clarifying performance-based award accelerations, and altering cash payment timings, aiming to better align executive compensation with market standards.

The most recent analyst rating on (PRCT) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on PROCEPT BioRobotics stock, see the PRCT Stock Forecast page.

Procept Biorobotics Reports Strong Q2 Growth Amid Challenges

Procept Biorobotics Corp. recently held its earnings call, revealing a generally positive sentiment. The company reported strong revenue growth, increased handpiece sales, improved gross margins, and favorable Medicare updates, all of which indicate positive operational momentum. Despite challenges such as the timing of system sales, increased operating expenses, continued net loss, and leadership transitions, the overall sentiment remains optimistic due to significant achievements and potential for future growth.

Procept Biorobotics Corp.’s Aquablation Therapy: A Promising Update for Prostate Cancer Treatment

The clinical study titled ‘PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs’ aims to evaluate the performance and safety of the AQUABEAM Robotic System. This system is used for the resection and removal of prostate tissue in patients with lower urinary tract symptoms and localized prostate cancer. The study’s significance lies in its potential to offer a minimally invasive treatment option, improving patient outcomes and quality of life.

PROCEPT BioRobotics Reports Strong Q2 2025 Growth

PROCEPT BioRobotics Corporation, a surgical robotics company specializing in urology, is known for its innovative solutions like Aquablation therapy, which aims to improve patient care and outcomes in the treatment of benign prostatic hyperplasia (BPH).